LY3200882

TGF-β receptor type 1/ALK5 (IC50 = 38.2 nM)

LY3200882 在体外以剂量依赖性方式有效抑制肿瘤和免疫细胞中 TGFβ 诱导的 SMAD 磷酸化[1]。 LY3200882 在三阴性乳腺癌原位 4T1-LP 模型中表现出有效的抗肿瘤作用，这种活性与肿瘤微环境中肿瘤浸润淋巴细胞的增加相关[1]。在体外免疫抑制实验中，LY3200882显示出能够拯救TGFβ1抑制或T调节细胞抑制的幼稚T细胞活性并恢复增殖[1]。 LY3200882 降低 NIH3T3 细胞活力，IC50 为 82.9 nM[2]。

---

作用机制研究表明LY3200882抑制多种促肿瘤活性。LY3200882在体外肿瘤和免疫细胞中有效抑制TGFβ介导的SMAD磷酸化。在体外免疫抑制实验中，LY3200882显示出挽救TGFβ1抑制或T调节性细胞抑制naïve T细胞活性和恢复增殖的能力。因此，LY3200882作为免疫调节剂具有良好的活性。此外，LY3200882在体外迁移试验中显示出抗转移活性，在体内实验转移性肿瘤模型（静脉注射三阴性乳腺癌EMT6-LM2模型）中也显示出抗转移活性[1]。

LY3200882（60 mg/kg；口服灌胃；每天两次；21 天；雌性 BALB/C 小鼠）治疗可显着减缓 CT26 模型中肿瘤的形成[2]。在体内，LY3200882 显着且剂量依赖性地抑制皮下肿瘤中 TGFβ 介导的 SMAD 磷酸化[1]。在实验性转移肿瘤模型（三阴性乳腺癌静脉EMT6-LM2模型）中，LY3200882表现出体内抗转移功效[1]。

---

在临床前肿瘤模型中，LY3200882在三阴性乳腺癌原位4T1-LP模型中表现出较强的抗肿瘤活性，这种活性与肿瘤微环境中肿瘤浸润淋巴细胞增强有关。在原位4T1-LP模型中观察到持久的肿瘤消退，并在所有小鼠中再次挑战先天性肿瘤导致完全排斥。最后，LY3200882在同基因CT26模型中显示出具有检查点抑制（抗pd - l1）的组合抗肿瘤益处。[1]

ALK5抑制活性[2]
采用发光ADP检测法评价化合物与ALK5的结合能力。将10 mM原液在DMSO中连续稀释3倍，得到10点稀释曲线，最终化合物浓度范围为3.333 μM ~ 0.5 nM。测定在1X激酶反应缓冲液中进行，缓冲液中含有40 mM Tris pH 7.5, 20 mM MgCl2, 0.1% BSA, 1 mM DTT，最终测定体积为5 μL。在384孔的实验板中，每孔加入2.5 μL的ALK5蛋白，最终浓度为3 μg/mL，每孔中溶解100 nL每种浓度的测试化合物。2.5 μL TGF-βR1肽，终浓度3 μg/mL， ATP，终浓度1 mM。28℃孵育120 min后，加入5 μL ADP-Glo™试剂终止激酶反应，消耗剩余ATP。28℃孵育120 min后，加入10 μL激酶检测试剂，将ADP转化为ATP，记录发光。

---

体外p38α酶活性测定[2]
所有酶促反应在28°C下进行，反应时间为40 min。25 μL的反应混合物中含有50 mM HEPES， pH为7.5,0.0015% Brij-35, 25 ng激酶，10 μM ATP和fam标记的肽。化合物在100 μM， 3倍稀释，10倍浓度下进行检测。该检测由ChemPartner进行。它通过定量测定激酶反应后溶液中剩余ATP的量来测量激酶活性。荧光信号与存在的ATP量相关，与激酶活性的量呈负相关。在XLFit excel插件版本5.4.0.8中计算IC50值，使用公式：Y=Bottom +(Top-Bottom)/(1+(IC50/X) ^Hill Slope)，其中X为化合物浓度，Y为抑制率（%）。

基于细胞的荧光素酶报告试验TGF-β 1型受体活性[2]
本实验的目的是在细胞基础上鉴定干扰SMAD 2,3依赖性基因表达的化合物，证明它们在细胞水平上抑制ALK5。以每孔4000个细胞的速度，在96孔板中，用DMEM培养基将已准备好的冷冻原液中的Luc-Smad 2/3-NIH3T3细胞进行平板培养。细胞贴壁过夜后，培养基改为2%胎牛血清。在DMSO中配制试验化合物，制成4mm的原液。将原液在DMSO中连续稀释4倍，得到8点稀释曲线，最终化合物浓度范围为20 μM ~ 1.22 nM，并加入待测化合物。24小时后，在每个孔中加入Glo Lysis Buffer和Bright-Glo Luciferase assay system，使孔体积翻倍。将等分液（180 μL）转移到白色实心底板上，在平板读取器上读取发光（读取1 s）。

Animal/Disease Models: BALB/C female mice (5-8 weeks old) injected with CT26 cells[2]
Doses: 60 mg/kg
Route of Administration: po (oral gavage); twice a day; for 21 days
Experimental Results: A statistically significant tumor growth delay in CT26 model was observed.

---

Pharmacokinetics procedures[2]
This study was conducted in BALB/C male subjects to investigate the pharmacokinetic profiles of test compounds. The mice were randomized and divided into two groups consisting of 3 mice/group. Prepare test compounds [15r (a LY3200882 analog)] in PEG200-EtOH-solutol-physiological saline (4:1:1:14) to make 0.5 mg/mL solutions for oral gavage and to make 0.1 mg/mL solutions for intravenous injection. Sample collection was performed as follows: 1) single oral administration (PO) group: 5 mg/kg, 0.2 mL/10 g; 2) single tail vein injection (IV) group: 1 mg/kg, 0.1 mL/10 g. Blood was collected from orbital venous plexus in heparinized EP tube at 5, 15, 30 min, 1, 2, 6, 10, 24 h after intravenous or oral administration, and the contents of the blood were analyzed by LC-MS/MS(API 4500).

---

In vivo tumor xenograft model[2]
A well-established tumorigenesis assay was used to evaluate the antitumor effect of compound 15r (a LY3200882 analog) in BALB/C female mice model. All mice were housed under standard specific-pathogen-free (SPF) conditions and the animal experiments strictly complied with protocols approved by the Animal Welfare and Ethics Committee (AWEC). 1 × 106 cells/mouse of CT26 cells were injected subcutaneously into the 5-to-8-week-old BALB/C female mice. All compounds were administrated by oral gavage. Mice were examined thrice a week for the development of tumors by palpation, and tumor volumes calculated using formula V = 0.5 × length × width2. The investigators were not blinded to allocation during experiments and outcome assessment. Mice were randomly allocated to three groups consisting of 6 mice/group by an independent person in the laboratory. No statistical method was used to predetermine sample size. The antitumor effect of the compound was assessed by tumor growth inhibition (TGI) or relative tumor proliferation rate (T/C): TGI(%) = [1-(Vt1-Vt0)/(Vc1-Vc0)] × 100%, where Vc1 and Vt1 are the mean volumes of control and treated groups at time of tumor extraction, while Vc0 and Vt0 are the same groups at the start of dosages; T/C (%) = TRTV/CRTV × 100%, where TRTV is the relative tumor volume (RTV) of treated groups, while CRTV is the RTV of control groups. (RTV = Vt/V0, Vt is the mean volumes of treated groups at time of tumor extraction, V0 is the mean volumes of the same groups at the start of dosages).

[1]. Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor. AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 955.

[2]. Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors. Eur J Med Chem. 2020 Apr 29;198:112354.

LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer).
TGFbeta Inhibitor LY3200882 is an orally bioavailable agent that targets transforming growth factor-beta (TGFb), with potential antineoplastic activity. Upon administration, LY3200882 specifically targets and binds to TGFb, which prevents both the binding of TGFb to its receptor TGFbR and TGFb-mediated signal transduction. This may lead to a reduction in TGFb-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors, and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, angiogenesis, and various immune responses.

---

The transforming growth factor β (TGFβ) signaling pathway is a pleiotropic cellular pathway that plays a critical role in cancer. In fact, aggressive tumors are typically associated with high ligand levels and thus associated with poor prognosis in various tumor types. Cancer cells use autocrine and paracrine TGFβ signaling to modulate tumor cells and the tumor microenvironment leading to a highly invasive and metastatic phenotype, inducing and increasing tumor vascularization, modulating the extracellular matrix in the stroma, and inhibiting immune surveillance and antitumor immunity. Clinical studies with galunisertib (aka LY2157299 monohydrate), a small molecule inhibitor targeting the TGFβ pathway, have provided proof of concept data supporting the role of TGFβ in cancer and the utility of targeting the TGFβ pathway. Here we describe the identification of LY3200882, a next generation small molecule inhibitor of TGF-β receptor type 1 (TGFβRI). The molecule is a potent, highly selective inhibitor of TGFβRI embodied in a structural platform with a synthetically scalable route. It is an ATP competitive inhibitor of the serine-threonine kinase domain of TGFβRI. In conclusion, we have developed a novel potent and highly selective small molecule inhibitor of TGFβRI for the treatment of cancer.[1]

---

Inhibition of transforming growth factor β (TGF-β) type 1 receptor (ALK5) provides a feasible approach for the treatment of fibrotic diseases and malignant tumors. In this study, we designed and synthesized a new series of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives, and evaluated biologically as TGF-β type 1 receptor inhibitors. The most potent compound 15r inhibited the ALK5 enzyme and NIH3T3 cell viability with IC50 values of 44 and 42.5 nM, respectively. Compound 15r also displayed better oral plasma exposure and excellent bioavailability than LY-3200882, and in vivo inhibited 65.7% of the tumor growth in a CT26 xenograft mouse model.[2]

C24H29N5O3

435.518765211105

435.227

C, 66.19; H, 6.71; N, 16.08; O, 11.02

1898283-02-7

121249291

Off-white to light yellow solid powder

2.1

94.3

2

7

7

32

612

0

O1CCC(CC1)C1C(=CN(C2CC2)N=1)OC1C=CN=C(C=1)NC1C=CN=C(C=1)C(C)(C)O

PNPFMWIDAKQFPY-UHFFFAOYSA-N

InChI=1S/C24H29N5O3/c1-24(2,30)21-13-17(5-9-25-21)27-22-14-19(6-10-26-22)32-20-15-29(18-3-4-18)28-23(20)16-7-11-31-12-8-16/h5-6,9-10,13-16,18,30H,3-4,7-8,11-12H2,1-2H3,(H,25,26,27)

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

配方 1 中的溶解度: ≥ 2.5 mg/mL (5.74 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

---

配方 2 中的溶解度: ≥ 2.5 mg/mL (5.74 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。
*20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。

---

View More

配方 3 中的溶解度: ≥ 2.5 mg/mL (5.74 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。